What are the appropriate indications for using a proton‑pump inhibitor in patients with chronic liver disease?

PPI Indications in Chronic Liver Disease

In patients with chronic liver disease (CLD), PPIs should only be prescribed for specific evidence-based indications, and inappropriate use—which occurs in 50-60% of cirrhotic patients—must be actively avoided due to increased risks of infections and mortality. 1, 2, 3

Appropriate Indications for PPIs in CLD

Definitely Indicated for Long-Term Use:

• Barrett's esophagus 1
• Severe erosive esophagitis (LA Classification grade C/D) 1
• Gastroprotection in high-risk patients: Those using aspirin/NSAIDs at high risk for GI bleeding 1
• Secondary prevention of peptic ulcers (without concomitant antiplatelet drugs) 1

Definitely Indicated for Short-Term Use (≤8 weeks):

• Ulcer prevention after variceal band ligation or sclerotherapy 1, 4
• Treatment of NSAID-related peptic ulcers 1
• H. pylori eradication 1
• Acute variceal hemorrhage management (short course only) 4

Conditionally Indicated:

• PPI-responsive GERD with documented recurrence upon cessation 1
• Esophageal strictures from GERD (peptic strictures) 1

Inappropriate Indications in CLD (Common Pitfalls)

The following are NOT valid indications and represent the most common misuse patterns in cirrhotic patients:

• Portal hypertensive gastropathy (PHG) - This is the most common inappropriate indication, accounting for 16-34% of misuse 2, 3, 5
• Long-term prophylaxis after variceal bleeding - PPIs should be discontinued after the acute phase and post-banding ulcer healing 2, 3, 5
• Stress ulcer prophylaxis in non-ICU patients 1, 2
• Corticosteroid or anticoagulant use alone (without additional GI bleeding risk factors) 3
• Functional dyspepsia without sustained PPI response 1
• Uninvestigated dyspepsia or GERD 1

Critical Considerations in CLD

Risk-Benefit Assessment:

PPIs in cirrhotic patients carry specific risks that must be weighed against benefits:

• Increased infection risk: Associated with spontaneous bacterial peritonitis and other infections due to gut microbiome alterations 2, 3, 6
• Hepatic encephalopathy risk 6
• Drug metabolism concerns: Pantoprazole and lansoprazole show 4-8 fold increased exposure and are considered unsafe in cirrhosis 6

Preferred PPI Selection by Child-Pugh Class:

• Child-Pugh A or B: Esomeprazole, omeprazole, or rabeprazole (with dose reduction for omeprazole/rabeprazole) 6
• Child-Pugh C: Only esomeprazole at maximum 20 mg daily 6
• Avoid: Pantoprazole and lansoprazole in all cirrhotic patients 6

Drug Interactions:

Be aware of interactions with hepatitis C direct-acting antivirals (DAAs). Glecaprevir concentrations decrease by 64% with omeprazole 40 mg, though this doesn't affect SVR. Avoid doses exceeding omeprazole 40 mg equivalent when using DAAs 7

De-Prescribing Algorithm for CLD Patients

Step 1: Document Current Indication Review why the PPI was started and whether that indication persists 1, 8

Step 2: Identify Inappropriate Use The following predict inappropriate PPI use in CLD:

• Child-Pugh Class C 2
• MELD score >18 2
• History of variceal bleeding (often leads to indefinite inappropriate continuation) 2, 5
• Multiple concomitant medications 5

Step 3: Discontinue if No Valid Indication

• Stop PPIs immediately in hospitalized cirrhotic patients without clear current indication 8
• Remove from discharge medications if indication resolved 3
• Consider abrupt discontinuation or dose tapering (both acceptable) 1

Step 4: Monitor After Discontinuation Warn patients about potential rebound acid hypersecretion causing transient symptoms 1

Key Clinical Pitfalls to Avoid

1. Continuing PPIs indefinitely after variceal bleeding: This represents 29-34% of inappropriate use. PPIs should stop after post-banding ulcers heal 2, 3, 5

2. Prescribing for PHG: No evidence supports PPI use for preventing PHG progression or bleeding 2, 3

3. Automatic hospital discharge prescriptions: 40-50% of cirrhotic patients are discharged on PPIs without valid indication 3, 9

4. Using wrong PPI in advanced cirrhosis: Pantoprazole and lansoprazole accumulate dangerously in cirrhosis 6

5. Failing to document indication: Regular review of ongoing indication is essential, particularly in patients with MELD ≤8 who show better adherence to appropriate use 9

The evidence strongly supports that inappropriate PPI use in CLD patients (occurring in 50-60% of cases) subjects them to unnecessary infection and mortality risks. 2, 3 Strict adherence to evidence-based indications and active de-prescribing when inappropriate is essential for patient safety.